Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Mona S. El Raziky"'
Publikováno v:
Egyptian Liver Journal, Vol 12, Iss 1, Pp 1-6 (2022)
Abstract Background Iron deficiency anemia is common among patients with chronic liver disease. Reticulocyte hemoglobin is a marker for iron availability in the bone marrow that is not affected by inflammation. Objective The aim of this study is to d
Externí odkaz:
https://doaj.org/article/247b9c24eec74103ac4766f00740e330
Autor:
Noha A.E. Yasin, Shereen Abdel Alem, Engy A. Mogahed, Hadeel Gamal Eldeen, Ahmed Nagy, Hala Abdullatif, Hanaa M. El-Karaksy, Mona S. El-Raziky
Publikováno v:
The Journal of Pediatrics. 233:126-131
To assess the degree of liver stiffness using transient elastography in Egyptian children infected with hepatitis C virus (HCV) at baseline and 1 year after achievement of sustained virologic response (SVR) with direct acting antivirals.This prospect
Publikováno v:
European Journal of Pediatrics. 179:719-726
This study aimed to detect etiologies and histopathological features of non-alcoholic fatty liver disease (NAFLD) in Egyptian children 10 years from hepatologist perspectives. Infants and children below 10 years of age with biopsy-proven fatty liver
Autor:
Nehal M El-Koofy, Ghada M Anwar, Mona S El-Raziky, Ahmad M El-Hennawy, Fatma M El-Mougy, Hanaa M El-Karaksy, Fetouh M Hassanin, Heba M Helmy
Publikováno v:
The Saudi Journal of Gastroenterology, Vol 18, Iss 1, Pp 44-49 (2012)
Background/Aim: To study the prevalence of metabolic syndrome (MS), insulin resistance (IR) and non-alcoholic fatty liver disease (NAFLD) in overweight/obese children with clinical hepatomegaly and/or raised alanine aminotransferase (ALT). Patients a
Externí odkaz:
https://doaj.org/article/dc54849e65584e26a02b3e19d54628b4
Autor:
Mariam El-Moslemany, Mona S. El-Raziky, M. Abo-Elsoud, Noha Musa, Engy A. Mogahed, Ihab Aboueleyoun
Publikováno v:
Archives of Medical Science.
IntroductionGlycogen storage disease III (GSD III) is an inborn error of carbohydrate metabolism that involves mainly the liver and skeletal muscles with rare potential systemic complications as osteoporosis. The aim of work of the current study was
Publikováno v:
Annals of Saudi Medicine, Vol 32, Iss 2, Pp 200-202 (2012)
BACKGROUND AND OBJECTIVE: The risk of blood-borne infections, especially hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infection still remains in developing countries among children receiving blood products as hemophiliacs, but the r
Externí odkaz:
https://doaj.org/article/c9afb4be987c4afc9b716e7a5e0d2dac
Autor:
Hala Abdullatif, Rania Ramzi, Basma Abd El Rasheed Abd El Zaher, Carolyne Ghobrial, Hanaa El-Karaksy, Mona S. El Raziky, Engy A. Mogahed
Publikováno v:
Clinical Drug Investigation. 39:857-864
Drug–drug interactions need to be considered to optimize the pharmacotherapeutic outcome of direct-acting antivirals. The aim of this study was to report on possible drug–drug interactions between ledipasvir/sofosbuvir and other medications recei
Publikováno v:
Egyptian Liver Journal, Vol 10, Iss 1, Pp 1-7 (2020)
Background The widespread use of abdominal ultrasonography in children documented increased detection rate of gallstones. The aim of this study was to assess the possible risk factors of gallstones and to detect the complication rate and outcome of t
Publikováno v:
Egyptian Pediatric Association Gazette, Vol 65, Iss 2, Pp 54-59 (2017)
Background Hepatobiliary complications are frequent among sickle cell disease patients. Sickle cell disease has been extensively studied. However, data about hepatobiliary abnormalities among the pediatric age group are limited. Objective This study
Autor:
Carolyne Ghobrial, Hala Abdullatif, Hanaa El-Karaksy, Mona S. El-Raziky, Engy A. Mogahed, Nehal El-Koofy, Mortada El-Shabrawi, Haytham Ghita, Sawsan Okasha, Sherif Baroudy
Publikováno v:
Journal of pediatric gastroenterology and nutrition. 67(5)
OBJECTIVES Recently, direct acting antivirals (DAAs), sofosbuvir (SOF) combined with ledipasvir (LED), were approved for treatment of hepatitis C virus (HCV)-infected children 12 years of age and older or weighting at least 35 kg for all HCV genotype